株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

エリスロポエチン (EPO) の世界市場

Global Erythropoietin (EPO) Market with Focus on Asia: Industry Analysis & Outlook 2016-2020

発行 Koncept Analytics 商品コード 252468
出版日 ページ情報 英文 72 Pages
即納可能
価格
本日の銀行送金レート: 1USD=114.58円で換算しております。
Back to Top
エリスロポエチン (EPO) の世界市場 Global Erythropoietin (EPO) Market with Focus on Asia: Industry Analysis & Outlook 2016-2020
出版日: 2016年11月05日 ページ情報: 英文 72 Pages
概要

当レポートでは、世界におけるエリスロポエチン (EPO) 市場について包括的な分析を提供しており、地域別の市場分析、市場の促進因子と課題、競合情勢、主要企業のプロファイルなどの情報とともにお届けいたします。

第1章 概要

  • エリスロポエチン (EPO)
  • 遺伝子組換え型ヒトエリスロポエチン(rHuEPO)
  • 貧血およびその他の内科疾患をターゲットにしたEPOの使用
  • EPOの用途と副作用

第2章 世界のEPO市場

  • EPO薬剤の売上
  • EPO薬剤市場の売上予測
  • EPOバイオシミラーの売上
  • EPOバイオシミラーの売上予測
  • 薬剤タイプ別のEPO市場
  • EPO市場の予測:用途別
  • EPO市場の予測:地域別

第3章 地域別市場

  • 米国
  • アジア太平洋地域

第4章 市場力学

  • 成長促進因子
  • 動向
  • 課題

第5章 競合情勢

  • 世界のEPO薬剤市場
  • 米国のEPO薬剤市場
  • アジア太平洋地域のEPO薬剤市場

第6章 企業プロファイル

  • Johnson & Johnson
  • Roche Holding AG
  • Teva Pharmaceutical Industries Limited

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次

Erythropoietin is a substance produced by the kidney that leads to the formation of red blood cells in the bone marrow. It is a glycoprotein hormone which regulates erythropoiesis (Red Blood Cell production). For erythrocyte precursors present in the bone marrow, EPO acts as a cytokine. Commonly referred to as hematopoietin or hemopoietin, erythropoietin is also known to have other biological functions, such as involvement in the wound healing cycle and brain's response to neuronal injury. People suffering from End Stage Renal Disease (ESRD), HIV or undergoing chemotherapy are not able to produce enough EPO on their own and thus, are administered with synthetic or recombinant erythropoietin which has the similar sequence of amino acids. Recombinant erythropoietin is a kind of therapeutic agent devised using DNA technology.

On the bases of their molecular structure, EPO drugs can be divided into five categories: epoetin-alfa, epoetin-beta, epoetin-omega, epoetin-delta and darbepoetin-alfa. Among these epoetin-alfa and darbepoetin-alfa are most commonly prescribed EPO drugs.

The global EPO drugs market is expected to experience negative growth rate, primarily due to expiry of patents of two most common EPO drugs, epoetin-alfa and darbepoetin-alfa, allowing the entry of biosimilars; posing a serious threat to EPO drugs market. However, the Asia-Pacific region is expected to experience boom period majorly due to improving disposable income and better government medical reimbursement policies.

The report "Global Erythropoietin (EPO) Market with Focus on Asia: Industry Analysis & Outlook (2016-2020)" analyzes the development of this market, with focus on the US and Asia-Pacific markets. The major trends, growth drivers as well as issues being faced by the market are discussed in detail in this report. The four major players: Johnson & Johnson, Amgen, Roche and Teva Pharmaceutical Industries Limited are being profiled along with their key financials and strategies for growth. The report contains a comprehensive analysis of the global EPO market along with the study of the regional markets.

Table of Contents

1. Overview

  • 1.1 Erythropoietin
  • 1.2 Recombinant Human Erythropoietin (rHuEPO)
  • 1.3 Applications of EPO and Adverse Effects

2. Global EPO Market

  • 2.1 Global EPO Drug Market by Value
  • 2.2 Global EPO Drug Market Forecast by Value
  • 2.3 Global EPO Biosimilar Market by Value
  • 2.4 Global EPO Biosimilar Market Forecast by Value
  • 2.5 Global EPO Market by Drug Type
  • 2.6 Global EPO Drug Market Forecast by Application
  • 2.7 Global EPO Drug Market by Region

3. Regional Markets

  • 3.1 The US
    • 3.1.1 The US EPO Drug Market Forecast by Value
    • 3.1.2 The US EPO Drugs Market by Applications
  • 3.2 Asia-Pacific
    • 3.2.1 China EPO Drug Market by Value
    • 3.2.2 China EPO Drug Market Forecast by Value
    • 3.2.3 China EPO Drug Market by Application
    • 3.2.4 Malaysia EPO Drug Market Forecast by Value
    • 3.2.5 Korea EPO Drug Market Forecast by Value
    • 3.2.6 Thailand EPO Drug Market Forecast by Value
    • 3.2.7 Philippines EPO Drug Market Forecast by Value
    • 3.2.8 Vietnam EPO Drug Market Forecast by Value

4. Market Dynamics

  • 4.1 Growth Drivers
    • 4.1.1 Rising Number of Patients Suffering from ESRD
    • 4.1.2 Increasing Global Healthcare Expenditure Per Capita
    • 4.1.3 Rising Global GDP Per Capita
    • 4.1.4 Escalating Aged Population
    • 4.1.5 Rising Cases of HIV and Cancer Induced Anemia
    • 4.1.6 Increasing Sales of Prescription Drugs
  • 4.2 Trends
    • 4.2.1 Entry of Biosimilar
    • 4.2.2 Shift from Short-Acting to Long-Acting EPO Drugs
    • 4.2.3 Underpenetrated Dialysis and Oncology Market in Asia
  • 4.3 Challenges
    • 4.3.1 Biosimilar Hampering the EPO Drug Market Growth
    • 4.3.2 Declining Price of EPO drugs
    • 4.3.3 High R&D Cost

5. Competitive Landscape

  • 5.1 Global EPO Drug Market
    • 5.1.1 Global EPO Drugs Market Share by Company
    • 5.1.2 Global EPO Drugs Market by Products
  • 5.2 The US EPO Drug Market
    • 5.2.1 The US EPO Drugs Market Share by Company
  • 5.3 Asia-Pacific EPO Drug Market
    • 5.3.1 China EPO Market Share by Company
    • 5.3.2 Japan EPO Market Share by Company

6. Company Profiles

  • 6.1 Johnson & Johnson
    • 6.1.1 Business Overview
    • 6.1.2 Financial Overview
    • 6.1.3 Business Strategies
  • 6.2 Roche Holding AG
    • 6.2.1 Business Overview
    • 6.2.2 Financial Overview
    • 6.2.3 Business Strategies
  • 6.3 Amgen Inc.
    • 6.3.1 Business Overview
    • 6.3.2 Financial Overview
    • 6.3.3 Business Strategies
  • 6.4 Teva Pharmaceutical Industries Limited
    • 6.4.1 Business Overview
    • 6.4.2 Financial Overview
    • 6.4.3 Business Strategies

List of Charts

  • Erythropoietin Response to Hypoxia
  • Types of Recombinant Human Erythropoietin (rHuEPO)
  • Global EPO Drug Market by Value (2011-2015)
  • Global EPO Drug Market Forecast by Value (2016-2020)
  • Global EPO Biosimilar Market by Value (2011-2015)
  • Global EPO Biosimilar Market Forecast by Value (2016-2020)
  • Global EPO Market by Drug Type (2015/2020)
  • Global EPO Market Forecast by Application (2020)
  • Global EPO Drug Market by Region (2015/2020)
  • The US EPO Drug Market Forecast by Value (2015-2020)
  • The US EPO Drugs Market by Applications (2015)
  • China EPO Drug Market by Value (2011-2015)
  • China EPO Drug Market Forecast by Value (2016-2020)
  • China EPO Drug Market by Application (2015)
  • Malaysia EPO Drug Market Forecast by Value (2015-2020)
  • Korea EPO Drug Market Forecast by Value (2015-2020)
  • Thailand EPO Drug Market Forecast by Value (2015-2020)
  • Philippines EPO Drug Market Forecast by Value (2015-2020)
  • Vietnam EPO Drug Market Forecast by Value (2015-2020)
  • Global ESRD Patients Volume (2011-2015)
  • Global Addressable Smartcard Market by Segments (2015-2020)
  • Global Healthcare Expenditure Per Capita (2011-2015)
  • Global GDP Per Capita (2011-2015)
  • Global Population above 64 Years (2011-2015)
  • Global New Cancer Patients by Volume (2011-2015)
  • Global Sales of Prescription Drugs (2011-2015)
  • Global Biosimilar Market by Value (2011-2015)
  • Global EPO Drugs Market Share by Company (2015)
  • The US EPO Drugs Market Share by Company (2015)
  • China EPO Market Share by Company (2015)
  • Japan Short-Acting EPO Market Share by Company (2015)
  • Johnson & Johnson Revenue by Segment (2015)
  • Johnson & Johnson Revenue and Net Income (2011-2015)
  • Johnson & Johnson R&D Expenditure (2013-2015)
  • Roche Holding AG Revenue by Segment (2015)
  • Roche Holding AG Revenue and Net Income (2011-2015)
  • Roche Holding AG R&D Expenditure (2013-2015)
  • Amgen Inc. Revenue by Product Segment (2015)
  • Amgen Inc. Revenue and Net Income (2011-2015)
  • Amgen Inc. R&D Expenditure (2013-2015)
  • Teva Revenue by Segment (2015)
  • Teva Revenue and Net Income (2011-2015)
  • Teva's R&D Expenditure (2013-2015)

List of Tables

  • EPO Biosimilar and Drugs by Company (2015)
  • Global EPO Drugs Market by Product (2015)
Back to Top